Department of Urology, San Giovanni Battista Hospital, University of Torino, Torino, Italy.
Unit of Oncology/Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy.
Clin Genitourin Cancer. 2023 Jun;21(3):416.e1-416.e10. doi: 10.1016/j.clgc.2022.11.012. Epub 2022 Dec 5.
The urological community's opinion over the management of men being found with pathologically positive nodes (pN+) following radical prostatectomy (RP) performed with curative intent after preoperative negative conventional staging (cN0M0) has never been assessed. This remains crucial, especially considering the advent of novel imaging modalities. Our aim was to investigate the current opinion on management of pN+ cN0M0 prostate cancer (PCa) in the European urological community.
Following validation, a 31-item survey, complying with the Cherries checklist, was distributed using a web link from December 2021 to April 2022 to 10 urological societies mailing list. Social media (Twitter, Facebook) were also used.
We received 253 replies. The majority were Urologists (96.8%), younger than 60 (90.5%); 5.2% did not have access to PET-scans; 78.9% believed pN+ is a multifaceted category; 10-years CSS was marked as 71 to 95% by 17.5%. Gold standard management was stated not being ADT by 80.8% and being RT±ADT by 52.3%. Early sRT±ADT was considered an option vs. aRT±ADT by 72.4%. In case of BCR 71% would perform and decide management based on PSMA-PET whilst 3.7% would not perform PSMA-PET. pN+ management is still unclear for 77.1%. On multivariate analysis PSMA-PET availability related to a lower and higher likelihood of considering aRT±ADT as standard and of considering early salvage versus aRT respectively (P < .05).
The Urological community has an acceptable awareness of pN+ disease and management, although it may overestimate disease aggressiveness. The majority consider pN+ PCa as a multifaceted category and rely on a risk-adapted approach. Expectant compared to immediate upfront management and new imaging modalities are increasingly considered.
根治性前列腺切除术(RP)后术前常规分期(cN0M0)为阴性,而术后发现病理性阳性淋巴结(pN+)的患者,泌尿外科医生对其管理意见从未被评估过。这一点非常重要,尤其是考虑到新的影像学模式的出现。我们的目的是调查欧洲泌尿外科医生对 cN0M0 前列腺癌(PCa)伴 pN+患者的管理意见。
在验证后,我们使用网页链接于 2021 年 12 月至 2022 年 4 月向 10 个泌尿外科协会的邮件列表分发了一份 31 项的调查问卷,该问卷符合 Cherries 清单。我们还使用了社交媒体(Twitter、Facebook)。
我们收到了 253 份回复。大多数回复者是泌尿科医生(96.8%),年龄小于 60 岁(90.5%);5.2%的人无法获得 PET 扫描;78.9%的人认为 pN+是一个多方面的类别;17.5%的人认为 10 年 CSS 为 71%至 95%。80.8%的人认为标准治疗方法不是 ADT,52.3%的人认为是 RT±ADT。72.4%的人认为早期 sRT±ADT 是一种选择,而不是 aRT±ADT。如果发生生化复发,71%的人将进行 PSMA-PET 并根据 PSMA-PET 决定治疗方案,而 3.7%的人将不进行 PSMA-PET。77.1%的人认为 pN+的管理仍然不清楚。多变量分析显示,PSMA-PET 的可用性与考虑 aRT±ADT 作为标准治疗和考虑早期挽救治疗而非 aRT 的可能性呈负相关(P <.05)。
泌尿外科医生对 pN+疾病及其管理有一定的认识,但可能高估了疾病的侵袭性。大多数人认为 pN+PCa 是一个多方面的类别,并且依赖于风险适应的方法。与立即进行治疗相比,他们更倾向于观察等待,并且越来越多地考虑新的影像学模式。